Andrew D Barreto1, Gary A Ford2, Loren Shen2, Claudia Pedroza2, Jon Tyson2, Chunyan Cai2, Mohammad H Rahbar2, James C Grotta2. 1. From the Department of Neurology (A.D.B., L.S.), Center for Clinical Research and Evidence-Based Medicine (A.D.B., C.P., J.T.), and Division of Clinical and Translational Sciences (DCTS), Department of Internal Medicine (C.C., M.H.R.), McGovern Medical School at The University of Texas Health Science Center at Houston; Newcastle Clinical Trials Unit (NCTU), Newcastle University, United Kingdom (G.A.F.); Division of Medical Sciences, Oxford University, and Oxford University Hospitals NHS Foundation Trust, Headley Way, United Kingdom (G.A.F.); and Clinical Innovation and Research Institute, Memorial Hermann Hospital, Texas Medical Center, Houston (J.C.G.). andrew.d.barreto@uth.tmc.edu. 2. From the Department of Neurology (A.D.B., L.S.), Center for Clinical Research and Evidence-Based Medicine (A.D.B., C.P., J.T.), and Division of Clinical and Translational Sciences (DCTS), Department of Internal Medicine (C.C., M.H.R.), McGovern Medical School at The University of Texas Health Science Center at Houston; Newcastle Clinical Trials Unit (NCTU), Newcastle University, United Kingdom (G.A.F.); Division of Medical Sciences, Oxford University, and Oxford University Hospitals NHS Foundation Trust, Headley Way, United Kingdom (G.A.F.); and Clinical Innovation and Research Institute, Memorial Hermann Hospital, Texas Medical Center, Houston (J.C.G.).
Abstract
BACKGROUND AND PURPOSE: We conducted a randomized exploratory study to assess safety and the probability of a favorable outcome with adjunctive argatroban, a direct thrombin-inhibitor, administered to recombinant tissue-type plasminogen activator (r-tPA)-treated ischemic stroke patients. METHODS: Patients treated with standard-dose r-tPA, not receiving endovascular therapy, were randomized to receive no argatroban or argatroban (100 μg/kg bolus) followed by infusion of either 1 (low dose) or 3 μg/kg per minute (high dose) for 48 hours. Safety was incidence of symptomatic intracerebral hemorrhage. Probability of clinical benefit (modified Rankin Scale score 0-1 at 90 days) was estimated using a conservative Bayesian Poisson model (neutral prior probability centered at relative risk, 1.0 and 95% prior intervals, 0.33-3.0). RESULTS:Ninety patients were randomized: 29 to r-tPA alone, 30 to r-tPA+low-dose argatroban, and 31 to r-tPA+high-dose argatroban. Rates of symptomatic intracerebral hemorrhage were similar among control, low-dose, and high-dose arms: 3/29 (10%), 4/30 (13%), and 2/31 (7%), respectively. At 90 days, 6 (21%) r-tPA alone, 9 (30%) low-dose, and 10 (32%) high-dose patients were with modified Rankin Scale score 0 to 1. The relative risks (95% credible interval) for modified Rankin Scale score 0 to 1 with low, high, and either low or high dose argatroban were 1.17 (0.57-2.37), 1.27 (0.63-2.53), and 1.34 (0.68-2.76), respectively. The probability that adjunctive argatroban was superior to r-tPA alone was 67%, 74%, and 79% for low, high, and low or high dose, respectively. CONCLUSIONS: In patients treated with r-tPA, adjunctive argatroban was not associated with increased risk of symptomatic intracerebral hemorrhage and provides evidence that a definitive effectiveness trial is indicated. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique Identifier: NCT01464788.
RCT Entities:
BACKGROUND AND PURPOSE: We conducted a randomized exploratory study to assess safety and the probability of a favorable outcome with adjunctive argatroban, a direct thrombin-inhibitor, administered to recombinant tissue-type plasminogen activator (r-tPA)-treated ischemic strokepatients. METHODS:Patients treated with standard-dose r-tPA, not receiving endovascular therapy, were randomized to receive no argatroban or argatroban (100 μg/kg bolus) followed by infusion of either 1 (low dose) or 3 μg/kg per minute (high dose) for 48 hours. Safety was incidence of symptomatic intracerebral hemorrhage. Probability of clinical benefit (modified Rankin Scale score 0-1 at 90 days) was estimated using a conservative Bayesian Poisson model (neutral prior probability centered at relative risk, 1.0 and 95% prior intervals, 0.33-3.0). RESULTS: Ninety patients were randomized: 29 to r-tPA alone, 30 to r-tPA+low-dose argatroban, and 31 to r-tPA+high-dose argatroban. Rates of symptomatic intracerebral hemorrhage were similar among control, low-dose, and high-dose arms: 3/29 (10%), 4/30 (13%), and 2/31 (7%), respectively. At 90 days, 6 (21%) r-tPA alone, 9 (30%) low-dose, and 10 (32%) high-dose patients were with modified Rankin Scale score 0 to 1. The relative risks (95% credible interval) for modified Rankin Scale score 0 to 1 with low, high, and either low or high dose argatroban were 1.17 (0.57-2.37), 1.27 (0.63-2.53), and 1.34 (0.68-2.76), respectively. The probability that adjunctive argatroban was superior to r-tPA alone was 67%, 74%, and 79% for low, high, and low or high dose, respectively. CONCLUSIONS: In patients treated with r-tPA, adjunctive argatroban was not associated with increased risk of symptomatic intracerebral hemorrhage and provides evidence that a definitive effectiveness trial is indicated. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique Identifier: NCT01464788.
Authors: Claudia Pedroza; Weilu Han; Van Thi Thanh Truong; Charles Green; Jon E Tyson Journal: Stat Methods Med Res Date: 2015-12-13 Impact factor: 3.021
Authors: Mohammad H Rahbar; Aisha S Dickerson; Chunyan Cai; Claudia Pedroza; Manouchehr Hessabi; Loren Shen; Renganayaki Pandurengan; Amber Nicole M Jacobs; Hari Indupuru; Melvin R Sline; Rigoberto I Delgado; Claire Macdonald; Gary A Ford; James C Grotta; Andrew D Barreto Journal: Contemp Clin Trials Date: 2015-08-13 Impact factor: 2.226
Authors: Nils Wahlgren; Niaz Ahmed; Antoni Dávalos; Gary A Ford; Martin Grond; Werner Hacke; Michael G Hennerici; Markku Kaste; Sonja Kuelkens; Vincent Larrue; Kennedy R Lees; Risto O Roine; Lauri Soinne; Danilo Toni; Geert Vanhooren Journal: Lancet Date: 2007-01-27 Impact factor: 79.321
Authors: Aravind Ganesh; Fahad S Al-Ajlan; Farahna Sabiq; Zarina Assis; Jeremy L Rempel; Kenneth Butcher; John Thornton; Peter Kelly; Daniel Roy; Alexandre Y Poppe; Tudor G Jovin; Thomas Devlin; Blaise W Baxter; Timo Krings; Leanne K Casaubon; Donald F Frei; Hana Choe; Donatella Tampieri; Jeanne Teitelbaum; Cheemun Lum; Jennifer Mandzia; Stephen J Phillips; Oh Young Bang; Mohammed A Almekhlafi; Shelagh B Coutts; Philip A Barber; Tolulope Sajobi; Andrew M Demchuk; Muneer Eesa; Michael D Hill; Mayank Goyal; Bijoy K Menon Journal: Stroke Date: 2016-11-10 Impact factor: 7.914
Authors: William N Whiteley; Jonathan Emberson; Kennedy R Lees; Lisa Blackwell; Gregory Albers; Erich Bluhmki; Thomas Brott; Geoff Cohen; Stephen Davis; Geoffrey Donnan; James Grotta; George Howard; Markku Kaste; Masatoshi Koga; Rüdiger von Kummer; Maarten G Lansberg; Richard I Lindley; Patrick Lyden; Jean Marc Olivot; Mark Parsons; Danilo Toni; Kazunori Toyoda; Nils Wahlgren; Joanna Wardlaw; Gregory J Del Zoppo; Peter Sandercock; Werner Hacke; Colin Baigent Journal: Lancet Neurol Date: 2016-06-08 Impact factor: 44.182
Authors: S Iris Deeds; Andrew Barreto; Jordan Elm; Colin P Derdeyn; Scott Berry; Pooja Khatri; Claudia Moy; Scott Janis; Joseph Broderick; James Grotta; Opeolu Adeoye Journal: Int J Stroke Date: 2020-12-09 Impact factor: 5.266
Authors: Gabriel C Müller; Samanta O Loureiro; Letícia F Pettenuzzo; Roberto F Almeida; Evandro Y Ynumaru; Pedro A Guazzelli; Fabíola S Meyer; Mayara V Pasquetti; Marcelo Ganzella; Maria Elisa Calcagnotto; Diogo O Souza Journal: Purinergic Signal Date: 2021-04-09 Impact factor: 3.765
Authors: Eivind Berge; William Whiteley; Heinrich Audebert; Gian Marco De Marchis; Ana Catarina Fonseca; Chiara Padiglioni; Natalia Pérez de la Ossa; Daniel Strbian; Georgios Tsivgoulis; Guillaume Turc Journal: Eur Stroke J Date: 2021-02-19